North America Epigenetics Diagnostic Market - Industry Trends and Forecast to 2028

Segmentation

Short Description
North America Epigenetics Diagnostic Market, By Product (Reagents, Kits, Instruments & Consumables, Bioinformatics Tools & Enzymes), Technology (DNA Methylation, Histone Methylation, Chromatin Structures, Histone Acetylation, Large Non-Coding RNA & MicroRNA Modification), Type of Therapy (Histone Deacetylase (HDAC) Inhibitors, DNA Methyltransferase (DNMT) Inhibitors & Others), Application (Oncology, Cardiovascular Diseases, Metabolic Diseases, Immunology, Inflammatory Diseases, Infectious Diseases & Others), End User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs) & Others), Distribution Channel (Direct Tender & Retail Sales), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2028

Market Definition:

The epigenetics diagnostic is the study of genetics, cellular and physical trait variations and developmental biology which is caused by the external environmental. This in turn affects genes and cellular ability to read genes without being affected by changes in genotype. The epigenetics changes result into changes in phenotype of organism rather than genotype, the underlying DNA and RNA sequence remains unchanged. The epigenetic changes are essential for development as they are dynamic and change with respect to environment.
The genetic expressions of organism are effected by epigenetics, which is making it the most crucial field of molecular biology and developmental genetics. Organizations, such as the National Center Institute, the National Institute of Health, and the International Human Epigenome Consortium, are funding and supporting research and development activities pertaining to the field of epigenetics. Epigenetics is also used to treat a variety of chronic diseases such as cancer, metabolic diseases, and others.
Market Segmentation:
North America epigenetics diagnostic market is categorized into six notable segments, which are based on product, technology, type of therapy, application, end user, and distribution channel.
 On the basis of product, the epigenetics diagnostic market is segmented into reagents, kits, instruments & consumables, bioinformatics tools, and enzymes

 On the basis of technology, the epigenetics diagnostic market is segmented into DNA methylation, histone methylation, chromatin structures, histone acetylation, large non-coding RNA, and microRNA modification

 On the basis of type of therapy, the epigenetics diagnostic market is segmented into histone deacetylase (HDAC) inhibitors, DNA methyltransferase (DNMT) inhibitors, and others

 On the basis of application, the epigenetics diagnostic market is segmented into oncology, cardiovascular diseases, metabolic diseases, immunology, inflammatory diseases, and others

 On the basis of end user, the epigenetics diagnostic market is segmented into academic and research institutes, pharmaceutical and biotechnology companies, contract research organizations (CROs), and others

 On the basis of distribution channel, the epigenetics diagnostic market is segmented into direct tender and retail sales

 Market Players

The major companies which are dealing in the North America epigenetics diagnostic market are listed below:
 Zymo Research Corporation
 PerkinElmer Inc.
 Diagenode
 F. Hoffman-La Roche Ltd
 EPICYPHER
 Promega Corporation
 QIAGEN
 Pacific Biosciences of California, Inc.
 Epigenomics AG
 Mnemo
 Reaction Biology
 Bio-Rad Laboratories, Inc.
 Agilent Technologies, Inc.
 Merck KGaA
  Illumina, Inc.
 ACTIVEMOTIF
 New England Biolabs
 Thermo Fisher Scientific, Inc.
 EpiGentek Group Inc.
 Enzo Life Sciences, Inc.
 Epizyme, Inc.
 GlaxoSmithKline plc.
 Eclipse BioInnovations
 MDxHealth
 Abcam plc
 Salarius Pharmaceuticals, Inc.
 Datar Cancer Genetics
 Bluestar Genomics Inc.

Methodology